Famotidine
Back to searchMolecule Structure
Scientific Name
Famotidine
Description of the Drug
Famotidine is a histamine H2 receptor antagonist used to treat duodenal ulcers, benign gastric ulcers, GERD, and Zollinger-Ellison syndrome.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00927
http://www.drugbank.ca/drugs/DB00927
Brand Name(s)
Famotidine, Famotidine preservative free, Famotidine preservative free (pharmacy bulk), Fluxid, Pepcid, Pepcid ac, Pepcid preservative free, Pepcid rpd
Company Owner(s)
Alkem Laboratories Ltd, Sun Pharmaceutical Industries Inc, Watson Laboratories Inc, Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div, Mankind Pharma Ltd, Abbvie Inc, Mylan Pharmaceuticals Inc, Hospira Worldwide, Inc, Zydus Pharmaceuticals Usa Inc, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Histamine H2 receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1941 |
Clinical Trial(s)
Unichem Links
| Atlas | famotidine | ||||
| SureChEMBL | SCHEMBL972 | SCHEMBL23804905 | |||
| PharmGKB | PA449586 | ||||
| Human Metabolome Database | HMDB0001919 | ||||
| DrugBank | DB00927 | ||||
| PubChem: Thomson Pharma | 14851333 | 14753540 | 14777800 | 14900130 | 14900131 |
| PubChem | 5353622 | 3325 | 5702160 | ||
| Mcule | MCULE-1972636463 | ||||
| NMRShiftDB | 20207393 | 20211263 | |||
| LINCS | LSM-5201 | ||||
| Nikkaji | J22.992J | ||||
| BindingDB | 50103514 | 50036754 | 22891 | ||
| EPA CompTox Dashboard | DTXSID5023039 | ||||
| DrugCentral | 1129 | ||||
| ChemicalBook | CB5706585 | ||||
| Guide to Pharmacology | 7074 | ||||
| rxnorm | FAMOTIDINE | PEPCID | |||
| PubChem: Drugs of the Future | 12013748 | ||||
| ChEBI | 4975 | ||||
| ZINC | ZINC000001530636 |
